The survival time of endometrial cancer with bone metastasis is related to the physical quality and severity of the disease, and it is recommended to actively receive standardized treatment to improve the prognosis of the disease and prolong the life span. Bone metastasis of endometrial cancer suggests that the disease has deteriorated and the prognosis is usually poor, so active treatment is needed to improve the symptoms, enhance the quality of life and prolong the survival time. The available treatment options include radiotherapy, chemotherapy, targeted therapy and other comprehensive treatments. Chemotherapy drugs include: cyclophosphamide, paclitaxel, cytarabine, etc.; targeted drugs include: trastuzumab, bevacizumab, etc.. They can effectively inhibit the growth rate of tumor cells and shrink the tumor foci. Drugs need to be used under the guidance of a doctor, adverse reactions are recommended to consult a doctor, drug allergy is prohibited. By actively cooperating with doctors to receive standardized treatment, it can prolong the survival time of patients and improve the prognosis of the disease, it is recommended to maintain a good attitude and adhere to the treatment.